Unigene Laboratories, Inc. will receive a $2.5 million payment to supply Novartis with specified quantities of a bulk peptide necessary to support Novartis’ development program for an osteoporosis treatment. Unigene will use its manufacturing technology to develop an FDA-compliant process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary. Some of this material may be used in clinical studies. In 2004, Novartis exclusively licensed U...